A5044999723- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Lung Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Genetic and Kidney Cyst Diseases
- Medical Imaging and Pathology Studies
- Tissue Engineering and Regenerative Medicine
- CAR-T cell therapy research
- Renal and related cancers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- Tracheal and airway disorders
- Cutaneous lymphoproliferative disorders research
- Head and Neck Cancer Studies
- Urological Disorders and Treatments
Memorial Sloan Kettering Cancer Center
2018-2024
Kettering University
2024
PURPOSE Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of activity atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A MIBC. METHODS Eligible MIBC (cT2-T4aN0M0) received a dose A, 2 weeks later every 21 days four cycles 3 before RC. The primary end point was non–muscle-invasive downstaging to < pT2N0. RESULTS Of 44 enrolled patients, 39 were evaluable. met, 27...
Purpose To compare the effect of autologous blood patch injection (ABPI) with that a hydrogel plug on rate pneumothorax at CT-guided percutaneous lung biopsy. Materials and Methods In this prospective randomized controlled trial ( https://ClinicalTrials.gov , NCT02224924), noninferiority design was used for ABPI, 10% margin when compared plug, primary outcome within 2 hours A type I error 0.05 90% power were specified target study population 552 participants (276 in each arm). From October...
4517 Background: Neoadjuvant GC is standard for pts with MIBC and can result in pathologic downstaging to non-MIBC ( < pT2N0) at radical cystectomy (RC), which correlates improved survival. Based on the known activity of A metastatic BC (mBC), we tested combination GC+A as neoadjuvant therapy a phase II trial (NCT02989584). Methods: Eligible (cT2-T4aN0M0) received single dose (1200 mg IV) and, two weeks later, began C (as either 70mg/m2 IV D1 or 35 mg/m2 D1,D8), G (1000 D8) every 21 days...
4584 Background: We previously reported the clinical outcomes of a positive multi-center phase II trial neoadjuvant gemcitabine (G) and cisplatin (C) plus atezolizumab (A) in patients with muscle-invasive bladder cancer (Funt, et al. JCO 2022). In this another GC pembrolizumab (Rose al, 2021), PD-L1 positivity by immunohistochemistry was not predictive non–muscle-invasive downstaging ( < pT2N0). Therefore, we investigated other pre-treatment tissue-based genomic gene expression biomarkers...
You have accessJournal of UrologyCME1 Apr 2023PD36-08 PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB Ali Mouzannar, Karissa Whiting, Irina Ostrovnaya, Andrew Katims, Trey Durdin, Zachary Feuer, Michael Lattanzi, Hikmat Al-Ahmadie, Colleen Quinlan, Min Teo, David Aggen, Hong Truong, Jeffrey Kamradt, Maged Khalil, Bradley Lash, Ashley Regazzi, Marwah Jihad, Neha Ratna, Abigail Boswell, Yuanquan Yang, Kamal Pohar, Harry Herr, Sherri...
620 Background: Existing data suggest that percutaneous renal mass ablation offers favorable rates of disease control with lower cost and fewer complications relative to surgical interventions. Despite increasing utilization, little is known about changes in practice patterns patient selection over time as new technologies have emerged indications for been refined. Methods: Institutional review board approval was granted a waiver informed consent from the multinational Ablation Renal Masses...